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treatment on cancer and healthy cells, and these effects are 
generally characterized by tumor control probability (TCP) 
and normal tissue complication probability (NTCP). 
Nowadays, many attempts to create toxicities models have 
been made, simply measuring the 3D dose distribution on 
organ at risks by equivalent uniform dose (EUD) or mean 
dose. Advances in computing and the availability of many 
Machine Learning algorithms allow to catch complex 
interactions between dose and non-dose factors. Aim of this 
study was to test an 'in house software' to elaborate 
predictive model on prostate cancer patients treated in 
exclusive setting. 
Materials and Methods: A prospective study was performed 
on prostate cancer patients, treated with volumetric Arc 
Therapy radiotherapy and Image guided radiotherapy 
technique. We delivered moderate hypofractionation with a 
simultaneous integrated boost (SIB). Clinical Target Volume 
(CTV) included: prostate (CTV1, 80 Gy) and seminal vesicles 
(CTV2, 72 Gy) in the largest part of sample. Cumulative dose-
volume histograms (DVHs) of calculated treatment plans were 
exported from the Eclipse TPS. Data were analyzed by a 
software package, written in R and internally developed, 
called MODDICOM. By specific functions created ad hoc, we 
analysed the impact of Vdose for gastrointestinal and 
genitourinary toxicity, both acute and late (using RTOG and 
CTCAE 4.0 scales). Dose from treatment planning and 
simulated delivery was evaluated to calculate the Niemierko's 
EUD-based NTCP and TCP values. To calculate the EUD-based 
NTCP, we used parameterizations of the dose-response 
characteristics using Lyman NTCP formula.  
Results:
A total of 123 patients were recruited. Using MODDICOM we 
found a significant correlation (Mann-Whitney Test p=0,054, 
Logistic Model p=0.00692, Cox Model p=0.0198) between a 
Vdose of 59,5 Gy and late rectal toxicity probability of Grade 
1, in terms of proctitis and rectal haemorrhage from CTCAE 
4.0. This result agrees with the literature, in particular with 
QUANTEC revision of constraints for Radiotherapy. Moreover, 
toxicity and rectal EUD significantly correlate (p=0.06827). A 
EUD based DVH-reduction method, was used by MODDICOM to 
compute NTCP. Our patients were distributed on or close to 
an S slope showing that 50% probability of late G1 rectal 
toxicity is present with a mean delivered uniform dose of 
66,5 Gy.  
Conclusions: MODDICOM, tested on this setting of patients, 
showed good proof of reliable, providing results according 
with the common criteria used to validate Radiation 
Treatment plans. The development of this software could 
help clinicians to elaborate predictive models, in order to 
analyze patients series for radiobiological modeling purposes.  
   
PO-0745   
Switch to PARP1-dependent endjoining: Olaparib-mediated 
radiosensitization in prostate cancer cells 
C. Petersen1, W.Y. Mansour1, A. Koetter1, E. Dikomey1 
1University Medical Center Hamburg - Eppendorf (UKE, 
Department of Radiation Oncology, Hamburg, Germany  
 
Purpose/Objective: Prostate cancer (PrCa) is the most 
common cancer for men with a ten-years overall survival (OS) 
between 60 and 70%. Radiotherapy, which is one of the main 
treatment for PrCa, is limited by normal tissue toxicity. 
Therefore, a further increase in OS requires a specific 
radiosensitisation of PrCa without further damage to normal 
tissue. It was tested by us whether targeting of repair of DNA 
double-strand breaks can be implemented for a specific 
radiosensitisation.  
Materials and Methods: Previously, we reported a functional 
hierarchy between DSB repair pathways to ensure faithful 
and fast repair. Deregulation of this hierarchy switches the 
repair to an inaccurate repair mode which is PARP1-
dependent (PARP1-EJ). In the current study, we investigated 
the hypothesis that this switch is responsible for PARPi-
mediated radiosensitization in tumor cells. To that end, we 
firstly analyzed the radiosensitization effect of Olaparib on 
15 different tumor cell lines. We characterized cells which 
are radiosensitized (responders) and others which are not.  
Results: By analysing several different tumor cell lines it is 
shown by us that PrCa cell lines often shift to this DSB repair 
mode. As a consequence in this PrCa cell lines DSB repair is 
depressed when PARP1 is knocked down by the specific 
inhibitor olaparib (responders). In contrast, no reduction in 
DSB repair was seen in cells still using the classical NHEJ 
(non-responders). In responders inhibition of PARP1 by 
olaparib also results in a drastic radiosensitisation, which was 
not seen for non-responding tumor cells and likewise not for 
normal cells. It was also shown by us that this shift to PARP1-
EJ results from defect in Ku-binding, which is the initial step 
of NHEJ. Biomarkers are now tested which can be used to 
detect PrCa shifted to PARP-EJ in order to identify patients 
which might be treated by RT in combination with PARP1 
inhibition. 
Conclusions: Overall our data indicate that in PrCa where 
DSB is shifted to the PARP1 dependent EJ a specific 
radiosensitisation is achieved by the PARP1 inhibitor olaparib 
without further increase in normal tissue toxicity. 
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